36564 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 

Country Title Application No. Patent No. 

United States ......... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–US–16 ...................................... 16/096,524 (371- 

national phase).

10,822,608 

United States ......... Oligonucleotide Analogues Targeting Human LMNA .................................................................................... 17/024,100.

Australia ................. Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–AU–03 ...................................... 2017258642.

Brazil ...................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–BR–04 ...................................... BR1120180722790.

Canada .................. Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CA–05 ...................................... 3,022,303.

China ...................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CN–06 ...................................... 201780040785.7.

Colombia ................ Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CO–07 ..................................... NC2018/0012783.

Eurasia ................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–EA–08 ...................................... 201892467.

Europe ................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–EP–09 ...................................... 17735676.3.

Hong Kong ............. Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–1–HK–17.

19126894.5.

India ....................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–IN–10 ....................................... 201847043433.

Japan ..................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–JP–11 ....................................... 2019–508165.

Korea (South) ........ Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–KR–12 ...................................... 10–2018–7034615.

Mexico .................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–MX–13 ..................................... MX/A/2018/013157.

New Zealand .......... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–NZ–14 ...................................... 747685.

Singapore ............... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–SG–15 ...................................... 11201809468X.

The patent rights in these inventions 

have been assigned to the Government 

of the United States of America, the 

University of Maryland, Sarepta 

Therapeutics, Inc, and the Progeria 

Research Foundation (PRF), co-owners 

of said rights, for commercial 

development and marketing. The rights 

to be granted by NHGRI are controlled 

by NHGRI by virtue of co-ownership 

and a license received to the listed 

intellectual property. The prospective 

patent license will be for the purpose of 

consolidating the patent rights to PRF. 

Consolidation of these co-owned rights 

is intended to expedite development of 

the invention, consistent with the goals 

of the Bayh-Dole Act codified as 35 

U.S.C. 200–212. The prospective patent 

license will be worldwide, exclusive, 

may be limited to those fields of use 

commensurate in scope with the patent 

rights, and will be sublicensable. 

The subject technology pertains to 

modified oligonucleotides (called 

phosphorodiamidate morpholino 

oligonucleotides or PMOs) targeted to 

pre-mRNA of human LMNA Lamin A 

gene. These PMOs can be used to 

correct aberrant splicing of LMNA gene 

known to be involved in HutchinsonGilford Progeria Syndrome (HGPS), and 

could be used in treating this ultra-rare 

disease and related laminopathies. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective Exclusive Patent 

License will be royalty bearing and may 

be granted unless, within fifteen (15) 

days from the date of this published 

notice, the NHGRI Technology Transfer 

Office receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Complete applications for a license 

that are timely filed in response to this 

notice will be treated as objections to 

this to the grant of the contemplated 

exclusive patent license. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 29, 2021. 

Claire T. Driscoll, 

Director, Technology Transfer Office, 

National Human Genome Research Institute, 

National Institutes of Health. 

[FR Doc. 2021–14702 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Mental Health Council. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Mental Health Council. 

Date: August 6, 2021. 

Time: 3:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Tracy Lynn Waldeck, 

Ph.D., Director, Division of Extramural 

Activities, National Institute of Mental 

Health, Neuroscience Center, 6001 Executive 

Boulevard, Room 4133, Rockville, MD 20892, 

(301) 480–6833, waldeckt@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nimh.nih.gov/about/advisory-boardsand-groups/namhc/index.shtml, where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: July 7, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14737 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Heart, Lung, 

and Blood Advisory Council. 

The meeting will be closed to the 

public in accordance with the 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 36565 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: August 24, 2021. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Laura K. Moen, Ph.D., 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6705 

Rockledge Drive, Room 206–Q, Bethesda, MD 

20892, 301–827–5517, moenl@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nhlbi.nih.gov/meetings/nhlbac/ 

index.htm, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: July 6, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14698 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, July 7, 

2021, 9:00 a.m. to July 8, 2021, 7:00 

p.m., National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

June 10, 2021, FR Doc 2021–12144, 86 

FR 30965. 

This notice is being amended to 

change the meeting date from July 7–8, 

2021 to July 28–29, 2021. The meeting 

time remains the same. The meeting is 

closed to the public. 

Dated: July 6, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14738 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Sleep Disorders Research 

Advisory Board. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

Date: August 5, 2021. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: The purpose of this meeting is to 

update the Advisory Board and public 

stakeholders on the progress of sleep and 

circadian research activities across NIH, and 

the activities of professional societies. 

Place: Virtual-Teleconference and 

Zoomgov. 

Telephone Access: 1–666–254–5252 

(Meeting ID: 160 375 9848 Passcode: 558748). 

Virtual Access: Meeting ID: 160 375 9848 

Passcode: 558748, https://nih.zoomgov.com/ 

j/1603759848?pwd=a1ZzMmdSZTJ4WTh

OWDBJQlRqbEYvUT09. 

Contact Person: Marishka Brown, Ph.D., 

SDRAB Executive Secretary, Director, 

National Center on Sleep Disorders Research, 

National Institutes of Health, National Heart, 

Lung, and Blood Institute, Division of Lung 

Diseases, 6705 Rockledge Drive, Suite 407B, 

Bethesda 20892, 301–435–0199, ncsdr@

nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: July 6, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14699 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: RP2 AAV-Based Gene 

Human Therapy for Ocular Diseases 

and Disorders Including XLRP 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to PTC 

Therapeutics GT, Inc. located in 100 

Corporate, Middlesex Business Center, 

South Plainfield, NJ 07080. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before July 27, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Hiba Alsaffar, Ph.D., 

Licensing and Patenting Manager at 

(240)-276–5530; or at Email: 

hiba.alsaffar@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

I. United States Provisional Patent 

Application No. 62/131,661 filed Mar. 


khammond on DSKJM1Z7X2PROD with NOTICES